with a variety of reagents. Alkylation of (3b) with either 2-furoyl chloride or chloroacetyl chloride gave the 2-N-substituted derivatives (9a,b). Benzofurano[3,2-b]4H-pyran derivative (12) was also prepared. The antimicrobial activity of the prepared compounds was tested.
Introduction
Coumarins are nowadays an important group of organic compounds that are used as bactericides [1] [2] [3] , fungicides [4] , anti-inflammatory [5] , anticoagulant [6] and antitumour agents [7, 8] . These pharmacological properties of coumarins aroused our interest in synthesizing several new compounds featuring different heterocyclic rings fused onto the coumarin moiety with the aim of obtaining more potent pharmacologically active compounds.
Results and Discussion
Condensation o f 4 -hydroxycoumarin (4-hydroxy-2H-1-benzopyran-2-one, 1) with α-cyano-pbromocinnamonitrile (2a) in ethanol containing a catalytic amount of piperidine afforded a product which may have two possible structures: 3a or 4a (Scheme 1).
Scheme 1
Structure 3a is favoured over 4a based on the 1 H-NMR spectra which revealed the presence of a signal at δ 4.5-5.0 ppm for one proton linked with a sp 3 carbon. Signals at a similar position have been observed for 4H-pyran [9] . If 4a were the reaction product, one would expect a 2H-pyran signal, appearing at lower values. The formation of 3a was assumed to proceed via addition of the coumarinyl C-3 to the activated double bond in 2a followed by cycloaddition of the Michael adduct. Compound 3b was prepared in similar way using α-carboethoxy-p-bromocinnamonitrile (2b, Scheme 1). It was reported that 2-amino -3-cyano-4H,5H-pyrano [3,2-c] [1] benzopyran-5-one derivatives react with triethyl orthoformate in acetic anhydride to produce the corresponding 3-cyano-2-ethoxy-methyleneamino derivatives [4, 9] . In this study the reaction of 3a with triethyl orthoformate in acetic anhydride afforded a product formulated as
benzopyran-6-one (7) rather than compound 8 (Scheme 2). Structure 7 was established for the reaction product b ased on the following data: a) i ts infrared spectrum revealed no absorption in the CN region, furthermore, it displayed absorption bands at 3448-3400 cm -1 as a broad band (NH 2 OH) and 1668 cm Tables 1 and 2 . It is apparent from the data listed in Table 1 that some of the synthesized compounds showed antibacterial activity comparable to that of amoxicillin, the reference drug used. However, concerning the activity against gram-positive bacteria (Bacillus subtilis), the pyrimidino[5`,4`-6,5]4H-pyrano [3,2-c] [1]-benzopyran-6-one (6) showed excellent activity, compounds 3b and 5 exhibit good activity , whereas compounds 7, 9b,10, 11 and 12 showed moderate activity . On the other hand, the Gram -negative bacteria ( Pseudomonas aurignosa) showed high responses to five of the prepared products. Dihydrobenzofurano[3,2-b]-4H-pyran (12) showed the maximum activity, higher than that of amoxicillin. Compound 6 exhibits excellent antibacterial activity towards Enterobacter aerogenes.
Concerning the data of antifungal activity in Table 2 , compound 5 showed excellent activity against Aspergillus niger, comparable to mycostatin , while compounds 7 and 8 exhibit good activity . Also, compound 9a displays moderate activity toward Penicillium italicum . In general, the data obtained from the microbiological screening showed that the activity of some synthesized compounds is equal to and sometimes greater than those of the reference drugs used. 
Experimental

General
Melting points were taken on an Electrothermal capillary melting point apparatus and are uncorrected. The microanalyses were done at Faculty of Scinece, King Khalid University. Infrared spectra were recorded on a Jasco FT/IR 460, using KBr disks.
1 H-NMR Spectra were recorded on JEOL EX-270 MHz NMR Spectrometer. Mass spectra were recorded on a Finnigan Mat SSQ-7000 mass spectrometer.
Biological Tests
Standard drugs (amoxicillin for bacteria and mycostatin for fungi) were used at a concentration of 1000 ppm for comparisons. The biological activity of these compounds have been evaluated by filter paper disc method [11] after dissolving them in N,N-dimethylformamide to obtain a 1mg/mL solution (1000 ppm). The inhibition zones of microbial growth surrounding the filter paper disc (5 mm) were measured in millimeters at the end of an incubation period of 3 days at 37°C for Echerichia coli and at 28°C for other bacteria and fungi. N,N-dimethylformamide alone showed no inhibation zone.
2-Amino-4-(4`-bromophenyl)-3-cyano-4H,5H-pyrano[3,2-c][1]benzopyran-5-one (3a).
A solution of 4-hydroxycoumarin (1, 1.62 g, 0.01 mole) and α-cyano -p-bromocinnamonitrile (2a, 2.32 g, 0.01 mole) in ethanol (20 mL) containing piperidine (0.5 mL) was heated for 30 min. The solid product that precipitated during the reflux was filtered off, dried and recrystallised from dioxane to give 3a (cf. 
2-Amino-4-(4`-bromophenyl)-3-carboethoxy-4H,5H-pyrano[3,2-c][1]-benzopyran -5-one (3b).
A solution of 4-hydroxycoumarin (1, 1.62 g, 0.01 mole) and α-carboethoxy-p-bromo-cinnamonitrile (2b, 2.79 g, 0.01 mole) in ethanol (20 mL) containing piperidine (0.5 mL) was heated under reflux for 8h. The solvent was removed under reduced pressure and the residue was triturated with methanol to give a yellow solid which filtered off, dried and recrystallised from benzene to produce 3b (cf. 
7-(p-Bromophenyl)-11-hydropyrimidino[5`,4`-6,5]4H-pyrano[3,2-c][1] -benzopyran-6,8-dione (5).
A mixture of 3a (3.9 g, 0.01 mole) and formic acid (10 mL) was heated at reflux for 10 h and then left to cool. The white crystals product thus formed was filtered off and recrystallised from ethanol to give 5 (cf. Table 3 
8-Amino-7-(p-bromophenyl)pyrimidino[5`,4`-6,5]4H-pyrano[3,2-c][1] -benzopyran-6-one (6).
Compound 3a (3.9 g, 0.01 mole) was added to a mixture of formamide (10 mL), formic acid (5mL) and dimethylformamide (5mL). The reaction mixture was heated at reflux for 10h and then left to cool. The solid product was filtered off and recrystallised from benzene to produce 6 (cf. Table 3 
8-Amino-7-(p-bromophenyl)-10-hydroxypyridino[3`,2`-6,5]4H-pyrano[3,2-c][1]benzopyran-6-one (7).
A mixture of 3a (3.9 g, 0.01 mole) and triethyl orthoformate (1.48 mL, 0.01 mole) in acetic anhydride (15 mL) was refluxed for 2h. The mixture was dissolved and then precipitated, cooled, filtered off and dried. The solid product was crystallised from DMF to give 7 (cf. 
2-N-furoylamino-3-carboethoxy-4-(p-bromophenyl)-4H,5H-pyrano[3,2-c][1]benzopyran-5-one (9a).
A mixture of 3b (4.4 g, 0.01 mole), 2-furoyl chloride (1.3 g, 0.01 mole) and potassium carbonate (1.38 g, 0.01mole) in dry acetone (20 mL) was heated under reflux for 4h. The reaction mixture after cooling was poured into water (100 mL). The solid that separated was collected, dried and recrystallised from ethanol to yield compound 9a (cf. Table 3 [3,2- A mixture of 9b (5.1 g, 0.01 mole) and sodium metal (0.23 g, 0.01 mole) in absolute ethanol (15 mL) was refluxed for 2h. After concentration and cooling, the mixture was poured into ice/acetic acid and allowed to stir for 1h. The insoluble product was removed by filtration, dried and recrystallised from dilute ethanol to produce 10 (cf. 
2-N-chloroacetylamino-3-carboethoxy-4-(p-bromophenyl)-4H,5H-pyrano
7-(p-Bromophenyl)-9-[(p-bromophenyl)carbonyl]-8-hydroxy-pyrrolo[3`,2`-5,6]4H-pyrano[3,2-c][1]-benzopyran-6-one (11).
A solution of 3b (1.02 g, 0.0025 mole) in pyridine (20 mL) was treated with 4-bromophenacyl bromide (5.08 g, 0.01 mole) and heated under reflux for 1h. The reaction mixture was poured into ice/HCl and the separated solid was filtered off. The product was crystallised from dimethylformamide to give 11 (cf. Table 3 
2-Amino-4-(p-bromophenyl)-3-[N-phenyl carbamido]-dihydrobenzofurano [3,2-b]-4H-pyran (12).
A mixture of 3b (1.02 g, 0.0025 mole) and anthranilic acid (1.26 g, 0.01 mole) in pyridine (20mL) was refluxed for 6h. The reaction mixture was poured into ice/HCl and the solid that separated was washed several times with water, dried and recrystallised from benzene to produce 12 (cf. 
